Chugai Pharmaceutical is a leading Japanese research-driven biopharmaceutical company focused on oncology, immunology, neuroscience, and other high-value therapeutic areas. Chugai Pharmaceutical Co., Ltd. is a drug manufacturer operating in Japan and is a subsidiary controlled by Hoffmann-La Roche, which owned 62% of the company as of June 30, 2014. Through its strategic relationship with Roche, Chugai combines its proprietary drug-discovery and antibody-engineering technologies with Roche’s global development and commercialization capabilities.
The company has established a strong portfolio of innovative medicines, including Hemlibra, Actemra, and Alecensa, while continuing to expand its pipeline through next-generation biologics and precision-medicine approaches. Chugai remains an important player in Japan’s pharmaceutical market, supported by its innovative pipeline, advanced R&D capabilities, and global partnership with Roche.
"Chugai stands at the forefront of Japan’s biopharma innovation, combining cutting-edge R&D with Roche’s global reach to advance next-generation medicines"
In 2026, Chugai Pharmaceutical is gaining significant attention in Japan’s pharmaceutical market, driven by a 14.7% year-on-year increase in core revenue to ¥663.3 billion and a 21.0% rise in core operating profit to ¥329.1 billion in the first half of the year. Growth was supported by strong biologic sales and international royalty income from key products such as Hemlibra and NEMLUVIO. Chugai also advanced its innovative pipeline, including the launch of ELEVIDYS as Japan’s first approved gene therapy for Duchenne muscular dystrophy, alongside continued progress in drug manufacturing, AI research, and companion diagnostics.
Delandistrogene moxeparvovec (ELEVIDYS)
Mechanism of Action: Gene transference Drug Class: Gene therapies Indication: Duchenne muscular dystrophy
Launched: In February 2026, ELEVIDYS® Intravenous Infusion launched as Japan’s first regenerative medical product for Duchenne muscular dystrophy, a rare, genetic and difficult-to-treat muscle-wasting disease Financial impact: ELEVIDYS launch supported Q1 growth, with core revenue up 11.5% to ¥321.7 billion and operating profit up 17.1% to ¥163.3 billion, at a record reimbursement price of nearly ¥305 million per patient.
Chugai’s February 2026 launch of ELEVIDYS (delandistrogene moxeparvovec) marked Japan’s first approved gene therapy for Duchenne muscular dystrophy (DMD). The one-time treatment uses an adeno-associated virus vector to deliver a gene encoding micro-dystrophin to skeletal and cardiac muscle cells, enabling production of a shortened functional dystrophin protein. The launch supported Chugai’s Q1 performance, with core revenue rising 11.5% to ¥321.7 billion and core operating profit increasing 17.1% to ¥163.3 billion, while ELEVIDYS entered the market at a record reimbursement price of nearly ¥305 million per patient.
The Growth Trifecta: Products, Alliances, and Royalty Revenue
Chugai Pharmaceutical has demonstrated strong and sustained revenue growth over the past seven years, with market revenue increasing from ¥786.9 billion in 2020 to ¥1,257.9 billion in 2025, and projected to reach ¥1,345.0 billion in 2026. Despite a temporary decline in 2023, the company quickly returned to growth, reflecting the resilience of its portfolio and commercial strategy. The forecasted 2026 performance is expected to be driven by strong domestic sales of key products such as Vabysmo and Polivy, increased overseas shipments of Hemlibra to Roche and Nemluvio, as well as higher royalty income and milestone-related revenues. This consistent upward trajectory highlights Chugai Pharmaceutical's strong market position and ability to generate growth through both product sales and strategic partnerships.
Seven-year market revenue of Chugai Pharmaceutical (2020-2026)
Fig 8: Market revenue of Chugai Pharmaceutical
"Chugai Pharmaceutical continues to accelerate growth through innovation, strategic partnerships, and a strong portfolio of blockbuster therapies."
Chugai's Growth Engine: Diversified Pipeline & Value Drivers
Strong late-stage oncology portfolio supported by Roche partnerships and next-generation targeted therapies
Chugai Pharmaceuticals maintains a robust oncology development pipeline spanning filed products, Phase III assets, and early-stage innovative programs. The portfolio is heavily focused on precision oncology, immuno-oncology, and novel antibody-based therapies, with many programs being developed in collaboration with Roche.
Among the most advanced programs, atezolizumab (Tecentriq) has multiple regulatory filings in Japan, including for adjuvant treatment of MRD-positive bladder cancer and maintenance therapy for locally advanced oesophagal cancer, highlighting near-term commercial opportunities. Another filed asset, giredestrant, is being pursued for both adjuvant breast cancer and unresectable or recurrent breast cancer, strengthening Chugai's presence in hormone receptor-positive breast cancer.
The late-stage pipeline is led by several promising Phase III programs. Alectinib (Alecensa) is being evaluated globally as maintenance therapy for Stage III NSCLC following chemoradiotherapy, while mosunetuzumab (Lunsumio) targets follicular lymphoma in both second-line and first-line settings. Additional key Phase III assets include divarasib, a KRAS G12C inhibitor for NSCLC; glofitamab for large B-cell lymphoma; and inavolisib, a PI3Kα inhibitor being developed across multiple breast cancer subtypes.
At the mid-stage level, glofitamab continues development in relapsed or refractory diffuse large B-cell lymphoma and mantle cell lymphoma, while inavolisib is also being investigated in endocrine-resistant breast cancer. These programs reinforce Chugai's strategy of expanding indications for high-value oncology assets.
The company's early-stage pipeline demonstrates a strong commitment to innovation. Notable Phase I candidates include codrituzumab for hepatocellular carcinoma, clesitamig, a trispecific antibody targeting DLL3/CD3/CD137, AUBE00, an oral Pan-KRAS inhibitor, and cevostamab, a bispecific antibody for multiple myeloma. These programs showcase Chugai's focus on novel mechanisms of action and next-generation antibody engineering.
While the company recently discontinued Phase III development of giredestrant in first-line breast cancer in combination with palbociclib, the overall oncology pipeline remains broad and diversified, with numerous regulatory milestones expected over the next several years and a balanced mix of near-term and long-term growth opportunities.
Advancing immune-mediated disease treatments through targeted antibodies and novel RNA-based therapies
Chugai Pharmaceuticals has built a diversified immunology pipeline focused on autoimmune, inflammatory, and rare kidney diseases, leveraging both antibody-based therapies and next-generation nucleic acid technologies. The portfolio includes near-term regulatory opportunities as well as innovative late-stage assets that address significant unmet medical needs.
Among the most advanced programs, obinutuzumab (Gazyva) and sparsentan have already been filed in Japan. Obinutuzumab, a humanized anti-CD20 monoclonal antibody partnered with Nippon Shinyaku, is under review for idiopathic nephrotic syndrome, while sparsentan has been filed for IgA nephropathy, expanding Chugai's presence in rare renal disorders.
The late-stage pipeline is anchored by obinutuzumab, which is being further developed in Phase III for lupus nephritis (projected submission in 2026) and extrarenal lupus (2027). Another notable Phase III asset is afimikibart, an anti-TL1A antibody being evaluated for ulcerative colitis and Crohn's disease, positioning Chugai in the rapidly growing inflammatory bowel disease market. In addition, sefaxersen, an antisense oligonucleotide targeting complement factor B mRNA, represents a novel approach for IgA nephropathy and highlights the company's expanding capabilities in RNA-based therapeutics.
Beyond late-stage development, Chugai is advancing innovative immunology programs such as DONG52, a multispecific antibody for celiac disease in Phase II, and RAY121, an anti-C1s recycling antibody for autoimmune diseases in Phase I. These assets demonstrate the company's commitment to developing differentiated therapies that address complex immune-mediated conditions.
Overall, Chugai's immunology portfolio combines near-term regulatory catalysts, led by obinutuzumab and sparsentan, with a strong late-stage pipeline featuring afimikibart and sefaxersen. This balanced strategy supports continued growth in immunology while reinforcing Chugai's focus on innovative biologics and precision medicine.
Near-term regulatory catalysts and innovative biologics strengthen Chugai's ophthalmology portfolio
Chugai Pharmaceuticals' ophthalmology pipeline is focused on advancing treatments for retinal and inflammatory eye diseases, with a strong emphasis on antibody-based therapies developed both independently and through its partnership with Roche. The portfolio contains several near-term regulatory opportunities alongside late-stage assets targeting significant unmet needs in ophthalmology.
Among the most advanced programs, satralizumab (Enspryng) has been filed in the U.S. for thyroid eye disease (TED), while the Port Delivery Platform with ranibizumab has been submitted in Japan for both neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). These filings provide important near-term commercialization opportunities and expand Chugai's presence in ophthalmic disorders.
The late-stage pipeline is led by satralizumab, which is also in Phase III development for TED in global markets outside the U.S., with a projected submission in 2026. Another key Phase III asset is vamikibart, an anti-IL-6 monoclonal antibody being developed for noninfectious uveitic macular edema, further strengthening Chugai's position in inflammatory eye diseases. In addition, faricimab (Vabysmo), a dual Anti-VEGF/Anti-Ang-2 bispecific antibody, is advancing in Phase III for non-proliferative diabetic retinopathy (NPDR), leveraging a differentiated mechanism designed to address retinal vascular disease.
Overall, Chugai's ophthalmology pipeline combines near-term regulatory filings with late-stage innovative biologics, particularly in retinal and inflammatory ophthalmic conditions. The portfolio is well-positioned to support future growth through a mix of established anti-VEGF technologies and novel IL-6-targeted therapies.
Advancing neuroimmunology, neurodegeneration, and rare neurological diseases through innovative biologics and gene therapies
Chugai Pharmaceuticals has established a focused neuroscience pipeline that spans neuroimmunological disorders, neurodegenerative diseases, and rare genetic conditions. The portfolio is anchored by late-stage programs with near-term regulatory potential, while also incorporating innovative antibody, nucleic acid, and gene therapy platforms through its collaboration with Roche.
The most advanced assets in the pipeline are satralizumab (Enspryng), which is being evaluated in Phase III for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and autoimmune encephalitis (AIE), with projected submissions in 2026 and 2027, respectively. These programs build upon satralizumab's established anti-IL-6 receptor mechanism and strengthen Chugai's position in neuroimmunology.
In the mid-stage pipeline, tominersen, an antisense oligonucleotide targeting HTT mRNA, is being evaluated for Huntington's disease, highlighting Chugai's commitment to RNA-based therapies for neurodegenerative disorders. Earlier-stage innovation is represented by prasinezumab, an anti-α-synuclein monoclonal antibody being investigated for Parkinson's disease.
Overall, Chugai's neuroscience portfolio combines late-stage neuroimmunology programs with innovative treatments for Alzheimer's disease, Huntington's disease, Parkinson's disease, and Duchenne muscular dystrophy, positioning the company to address significant unmet needs across both common and rare neurological conditions.
Late-stage hematology portfolio focused on complement inhibition and next-generation coagulation therapies
Chugai Pharmaceuticals' hematology pipeline is concentrated on rare blood disorders and bleeding diseases, featuring a strong portfolio of Phase III assets developed in collaboration with Roche. The pipeline leverages the company's expertise in antibody engineering to address significant unmet needs in hematology through innovative subcutaneous therapies.
The most advanced program is crovalimab (PiaSky), an anti-C5 recycling antibody being developed for atypical hemolytic uremic syndrome (aHUS), with a projected global submission in 2026. The asset represents an important addition to the complement-mediated disease space and has the potential to provide a more convenient treatment option through subcutaneous administration.
The pipeline also includes zenozocimig (NXT007/RG6512), a next-generation anti-coagulation factor IXa/X bispecific antibody being developed for Hemophilia A, with a projected submission in 2028. Designed to improve upon existing coagulation factor replacement approaches, zenozocimig highlights Chugai's continued innovation in hemophilia treatment.
Overall, Chugai's hematology pipeline is a focused late-stage portfolio characterized by three Phase III programs, led by crovalimab, emicizumab, and zenozocimig. Together, these assets position the company for continued growth in rare hematological diseases while reinforcing its leadership in antibody-based therapeutics and coagulation disorder management.
Building a diversified portfolio in cardiometabolic and specialty diseases through innovative RNA, peptide, and antibody technologies
Chugai Pharmaceuticals' Other Diseases pipeline focuses on addressing major chronic conditions such as hypertension and obesity while also exploring novel treatments for postoperative complications and immune-mediated disorders. The portfolio combines innovative modalities, including RNA interference (RNAi), peptide therapeutics, and engineered antibodies, providing a diversified source of future growth beyond the company's core therapeutic areas.
The most advanced assets are in Phase III, led by zilebesiran, an RNAi therapeutic partnered with Alnylam Pharmaceuticals for hypertension. By targeting angiotensinogen (AGT), zilebesiran represents a novel approach to long-term blood pressure control. Another key late-stage program is enicepatide, a long-acting GLP-1/GIP receptor agonist being developed for obesity, positioning Chugai within the rapidly expanding obesity treatment market.
In Phase II, Chugai is advancing emugobart, an anti-latent myostatin sweeping antibody for obesity. This differentiated mechanism may offer additional benefits in body composition management and further strengthens the company's growing presence in metabolic disease therapeutics.
The early-stage pipeline includes REVN24, a small-molecule candidate being investigated for postoperative complications following cardiac surgery, as well as RAY121, an anti-C1s recycling antibody targeting immune-mediated diseases. These programs demonstrate Chugai's commitment to exploring novel therapeutic approaches across a broad range of disease areas.
Overall, Chugai's Other Diseases pipeline is anchored by late-stage candidates zilebesiran and enicepatide, while innovative programs such as emugobart, REVN24, and RAY121 provide longer-term opportunities. The portfolio reflects the company's strategic expansion into large commercial markets, particularly cardiovascular and metabolic diseases, supported by advanced biologic and nucleic acid technologies.
